Trial · NCT00066365
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Status of FAS Ligand in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 0 | 7 | participants | |
| Status of FAS Ligand in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 1 | 5 | participants | |
| Status of FAS Ligand in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 2 | 1 | participants | |
| Status of FAS Ligand in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 3 | 1 | participants | |
| Presence of FAS in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 0 | 5 | participants | |
| Presence of FAS in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 1 | 5 | participants | |
| Presence of FAS in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 2 | 2 | participants | |
| Presence of FAS in Pre-chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 3 | 2 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 1 (Unilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 0 | 16 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 0 | 7 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 1 (Unilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 1 | 4 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 1 | 2 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 1 (Unilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 2 | 1 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 2 | 2 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 1 (Unilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 3 | 1 | participants | |
| FAS Ligand in Post Chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 3 | 2 | participants | |
| FAS Status in Post Chemotherapy Sample | Group 1 (Unilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 0 | 14 | participants | |
| FAS Status in Post Chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 0 | 5 | participants | |
| FAS Status in Post Chemotherapy Sample | Group 1 (Unilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 1 | 4 | participants | |
| FAS Status in Post Chemotherapy Sample | Group 2 (Bilateral Recurrence) - Sargramostim and Thoractomy | IHC Category 1 | 4 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00066365/results